CMS's price-substitution policy has saved $76 million for Medicare by correcting drug pricing identified by the Office of Inspector General, improving cost efficiency while maintaining access.
Recent Republican-led legislative changes delay Medicare drug price negotiations for costly cancer treatments, maintaining high patient costs and impacting seniors and disabled Americans.
CMS's 2026 proposed rules for Medicare Part B include major updates to average sales price calculations, Inflation Reduction Act compliance, ASP documentation, and Medicare inflation rebates affecting government pricing.
Novo Nordisk expands access to Wegovy with a new self-pay pricing program and pursues legal actions against unauthorized compounded drug sales, impacting the obesity treatment market.
Pfizer and other pharmaceutical firms have discussed most-favored-nation drug pricing with the U.S. government, highlighting potential impacts on insurance and payer strategies.
New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.
Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.
The U.S. administration advances a 'most favored nation' drug pricing policy to align Medicare prices with global low points, aiming to reduce prescription costs amid industry resistance and anticipated legal challenges.
President Trump's executive order and CMS initiatives mark significant moves to reduce drug prices through broadened Medicare price negotiations including Part B drugs, impacting pharmaceutical industry dynamics and regulatory compliance.
CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.
